Race Oncology (Race Oncology) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Race Oncology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Race Oncology's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Race Oncology could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Race Oncology's Cash-to-Debt or its related term are showing as below:

RAONF' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 7 years, Race Oncology's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

RAONF's Cash-to-Debt is ranked better than
99.74% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs RAONF: No Debt

Race Oncology Cash-to-Debt Historical Data

The historical data trend for Race Oncology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Race Oncology Cash-to-Debt Chart

Race Oncology Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

Race Oncology Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial										No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of Race Oncology's Cash-to-Debt

For the Biotechnology subindustry, Race Oncology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Race Oncology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Race Oncology's Cash-to-Debt falls into.

Race Oncology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Race Oncology's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Race Oncology had no debt ⁽¹⁾.

Race Oncology's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Race Oncology had no debt ⁽¹⁾.

Race Oncology (OTCPK:RAONF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Race Oncology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Race Oncology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Race Oncology (Race Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (OTCPK:RAONF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

RAC:Australia

Address

1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000

Website

https://www.raceoncology.com

Race Oncology Ltd is a specialty pharmaceutical company. It is engaged in the development and marketing of pharmaceutical drugs for the treatment of Cancer. Its product includes Bisantrene, a cancer chemotherapy drug. Its operating segments include research into oncology drugs, Zantrene and the manufacturing and distribution of the drug for clinical trials.